US pharma execs join Algeta board
pharmafile | April 29, 2010 | Appointment | Research and Development | Algeta, appointment, research and development
Oslo-based oncology company Algeta has added Judith Hemberger and Kapil Dhingra to its board of directors.
Judith Hemberger has more than 30 years’ of global pharmaceutical and biotech industry experience, co-founding Pharmion Corporation in 2000 and serving as its chief operating officer until 2006.
Prior to that, she served as senior VP of business development at vaccine technology company AVAX Technologies.
She currently serves on the board of directors of VasoGenix Pharmaceuticals and Chroma Therapeutics, and has previous board experience with companies such as Marion Merrell Dow, Pharmion and PRA International.
Kapil Dhingra formerly held the roles of vice president, head of the oncology disease biology leadership team, and head of the oncology clinical development at Hoffmann-La Roche, where he worked between 1999-2008.
For three years prior to this, he worked as a clinical and senior clinical research physician with Lilly.
Stein Annexstad, chairman of Algeta, said: “We are very pleased to welcome Judy and Kapil to the Algeta Board. Between them, they have a wealth of experience in the US and global pharma industry and particularly in the clinical and commercial development of innovative targeted cancer therapies.
“We look forward to the valuable contributions they will make to the successful continued development of Alpharadin, the building of our US commercial operations, and our longer-term ambitions to develop the business via our thorium technology.
“We would also like to thank Shahzad Malik, Inga Loen and Jens Petter Falck, who stepped down from the board at the AGM, for their efforts and input over their respective periods with the company.”
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
